Roche, a Swiss pharmaceutical company, plans to acquire Brisbane, Calif.-based InterMune, a biotech firm, for $8.3 billion, according to a Wall Street Journal report.
Roche largely focuses on cancer and autoimmune-focused diagnostics and treatments. This acquisition will expand Roche's offering to include InterMune's respiratory offerings.
More articles on acquisitions:
Cleveland Clinic finalizes Akron General minority ownership deal
Duke LifePoint, Conemaugh Health reach definitive acquisition agreement
Allergan, Salix in potential merger talks